These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22650222)

  • 1. The glycocalyx and cardiovascular disease in diabetes: should we judge the endothelium by its cover?
    Lemkes BA; Nieuwdorp M; Hoekstra JB; Holleman F
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S3-10. PubMed ID: 22650222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability.
    Nieuwdorp M; Meuwese MC; Mooij HL; Ince C; Broekhuizen LN; Kastelein JJ; Stroes ES; Vink H
    J Appl Physiol (1985); 2008 Mar; 104(3):845-52. PubMed ID: 18162484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial progenitor cells in diabetes mellitus.
    Menegazzo L; Albiero M; Avogaro A; Fadini GP
    Biofactors; 2012; 38(3):194-202. PubMed ID: 22488933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glycocalyx is an active part of the endothelium].
    Hahn R
    Lakartidningen; 2016 May; 113():. PubMed ID: 27187696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial glycocalyx: sweet shield of blood vessels.
    Van Teeffelen JW; Brands J; Stroes ES; Vink H
    Trends Cardiovasc Med; 2007 Apr; 17(3):101-5. PubMed ID: 17418372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus.
    Broekhuizen LN; Lemkes BA; Mooij HL; Meuwese MC; Verberne H; Holleman F; Schlingemann RO; Nieuwdorp M; Stroes ES; Vink H
    Diabetologia; 2010 Dec; 53(12):2646-55. PubMed ID: 20865240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glycocalyx is present as soon as blood flow is initiated and is required for normal vascular development.
    Henderson-Toth CE; Jahnsen ED; Jamarani R; Al-Roubaie S; Jones EA
    Dev Biol; 2012 Sep; 369(2):330-9. PubMed ID: 22820069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit.
    Becker BF; Chappell D; Jacob M
    Basic Res Cardiol; 2010 Nov; 105(6):687-701. PubMed ID: 20859744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist-induced impairment of glycocalyx exclusion properties: contribution to coronary effects of adenosine.
    VanTeeffelen JW; Brands J; Vink H
    Cardiovasc Res; 2010 Jul; 87(2):311-9. PubMed ID: 20418474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early microvascular changes with loss of the glycocalyx in children with type 1 diabetes.
    Nussbaum C; Cavalcanti Fernandes Heringa A; Mormanova Z; Puchwein-Schwepcke AF; Bechtold-Dalla Pozza S; Genzel-Boroviczény O
    J Pediatr; 2014 Mar; 164(3):584-9.e1. PubMed ID: 24367980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endothelial glycocalyx: a review of the vascular barrier.
    Alphonsus CS; Rodseth RN
    Anaesthesia; 2014 Jul; 69(7):777-84. PubMed ID: 24773303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity.
    Bakker W; Eringa EC; Sipkema P; van Hinsbergh VW
    Cell Tissue Res; 2009 Jan; 335(1):165-89. PubMed ID: 18941783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hydrodynamically relevant endothelial cell glycocalyx observed in vivo is absent in vitro.
    Potter DR; Damiano ER
    Circ Res; 2008 Apr; 102(7):770-6. PubMed ID: 18258858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrokinetic effect of the endothelial glycocalyx layer on two-phase blood flow in small blood vessels.
    Liu M; Yang J
    Microvasc Res; 2009 Jun; 78(1):14-9. PubMed ID: 19362568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
    Monti LD; Setola E; Fragasso G; Camisasca RP; Lucotti P; Galluccio E; Origgi A; Margonato A; Piatti P
    Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E54-E59. PubMed ID: 16174656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial Glycocalyx Impairment in Disease: Focus on Hyaluronan Shedding.
    Dogné S; Flamion B
    Am J Pathol; 2020 Apr; 190(4):768-780. PubMed ID: 32035885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease.
    Broekhuizen LN; Mooij HL; Kastelein JJ; Stroes ES; Vink H; Nieuwdorp M
    Curr Opin Lipidol; 2009 Feb; 20(1):57-62. PubMed ID: 19106708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects.
    Masola V; Zaza G; Onisto M; Lupo A; Gambaro G
    Int Angiol; 2014 Jun; 33(3):243-54. PubMed ID: 24936533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial glycocalyx is damaged in diabetic cardiomyopathy: angiopoietin 1 restores glycocalyx and improves diastolic function in mice.
    Qiu Y; Buffonge S; Ramnath R; Jenner S; Fawaz S; Arkill KP; Neal C; Verkade P; White SJ; Hezzell M; Salmon AHJ; Suleiman MS; Welsh GI; Foster RR; Madeddu P; Satchell SC
    Diabetologia; 2022 May; 65(5):879-894. PubMed ID: 35211778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes and protein metabolism.
    Møller N; Nair KS
    Diabetes; 2008 Jan; 57(1):3-4. PubMed ID: 18165354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.